Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Sebastian Johansson

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|April 29, 2021
[Hypersexuality]Katja Wium Geiker, Annamaria Giraldi, Karl Sebastian Johansson, et al.
Expert Opinion on Pharmacotherapy|February 29, 2020
Clinical pharmacology of imeglimin for the treatment of type 2 diabetesKarl Sebastian Johansson, Andreas Brønden, Filip Krag Knop, et al.
Drugs & Aging|September 1, 2023
Methodological Considerations for Describing Medication Changes in Relation to Clinical Events and Death: An Applied Example in Patients with Type 2 Diabetes and CancerKarl Sebastian Johansson, Tonny Studsgaard Petersen, Mikkel Bring Christensen, et al.
Diabetes Care|July 12, 2024
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication ExpensesKarl Sebastian Johansson, Espen Jimenez-Solem, Tonny Studsgaard Petersen, et al.
Diabetes Care|May 6, 2024
Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020Karl Sebastian Johansson, Espen Jimenez-Solem, Tonny Studsgaard Petersen, et al.
Expert Opinion on Drug Discovery|July 11, 2020
What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipelineKarl Sebastian Johansson, David Peick Sonne, Filip Krag Knop, et al.
The Lancet. Healthy Longevity|December 2, 2023
Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020Karl Sebastian Johansson, Cille Bülow, Espen Jimenez-Solem, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 22, 2023
Physician-led medication reviews in polypharmacy patients treated with at least 12 medications in a type 2 diabetes outpatient clinic: A randomised trialKarl Sebastian Johansson, Jonatan Kornholt, Cille Bülow, et al.
Ugeskrift for Laeger|December 15, 2020
[Local anaesthetic systemic toxicity]Karl Sebastian Johansson, Lotte Christine Groth Høgberg, Mikkel Bring Christensen, et al.
Danish Medical Journal|April 29, 2022
Drug use in patients with short bowel syndrome and intestinal failureMette Medom Vorre, Karl Sebastian Johansson, Kristian Asp Fuglsang, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|April 29, 2021
[Hypersexuality]Katja Wium Geiker, Annamaria Giraldi, Karl Sebastian Johansson, et al.
Expert Opinion on Pharmacotherapy|February 29, 2020
Clinical pharmacology of imeglimin for the treatment of type 2 diabetesKarl Sebastian Johansson, Andreas Brønden, Filip Krag Knop, et al.
Drugs & Aging|September 1, 2023
Methodological Considerations for Describing Medication Changes in Relation to Clinical Events and Death: An Applied Example in Patients with Type 2 Diabetes and CancerKarl Sebastian Johansson, Tonny Studsgaard Petersen, Mikkel Bring Christensen, et al.
Diabetes Care|July 12, 2024
Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication ExpensesKarl Sebastian Johansson, Espen Jimenez-Solem, Tonny Studsgaard Petersen, et al.
Diabetes Care|May 6, 2024
Increasing Medication Use and Polypharmacy in Type 2 Diabetes: The Danish Experience From 2000 to 2020Karl Sebastian Johansson, Espen Jimenez-Solem, Tonny Studsgaard Petersen, et al.
Expert Opinion on Drug Discovery|July 11, 2020
What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipelineKarl Sebastian Johansson, David Peick Sonne, Filip Krag Knop, et al.
The Lancet. Healthy Longevity|December 2, 2023
Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020Karl Sebastian Johansson, Cille Bülow, Espen Jimenez-Solem, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 22, 2023
Physician-led medication reviews in polypharmacy patients treated with at least 12 medications in a type 2 diabetes outpatient clinic: A randomised trialKarl Sebastian Johansson, Jonatan Kornholt, Cille Bülow, et al.
Ugeskrift for Laeger|December 15, 2020
[Local anaesthetic systemic toxicity]Karl Sebastian Johansson, Lotte Christine Groth Høgberg, Mikkel Bring Christensen, et al.
Danish Medical Journal|April 29, 2022
Drug use in patients with short bowel syndrome and intestinal failureMette Medom Vorre, Karl Sebastian Johansson, Kristian Asp Fuglsang, et al.
Pageof 2